Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HLX43 |
| Synonyms | |
| Therapy Description |
HLX43 is an antibody-drug conjugate (ADC) comprising an antibody targeting CD274 (PD-L1) linked to a camptothecin-based toxin, which potentially inhibits tumor growth (Ann Oncol (2023) 34 (suppl_2): S483). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HLX43 | HLX 43|HLX-43 | PD-L1/PD-1 antibody 133 | HLX43 is an antibody-drug conjugate (ADC) comprising an antibody targeting CD274 (PD-L1) linked to a camptothecin-based toxin, which potentially inhibits tumor growth (Ann Oncol (2023) 34 (suppl_2): S483). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06907615 | Phase II | HLX43 | A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) | Recruiting | USA | 1 |